PFIZER INC Equity Securities, FV-NI, Unrealized Gain (Loss)
PFIZER INC (PFE) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$53.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-04
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-28 was -$53.00M, a 181.54% decline year-over-year.
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-29 was -$15.00M.
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $1.22B, a 37.81% increase year-over-year.
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-28 was -$23.00M.
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$32.00M.
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$114.00M.
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$165.00M.
- PFIZER INC equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$1.40B, a 210.76% decline from fiscal 2021.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-28 | -$53.00M 10-Q · filed 2026-08-04 | -$68.00M 10-Q · filed 2026-08-04 | $1.15B derived: sum of 3 quarters · filed 2026-08-04 | $1.13B derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-29 | -$15.00M 10-Q · filed 2026-05-05 | $1.21B derived: sum of 2 quarters · filed 2026-05-05 | $1.18B derived: sum of 3 quarters · filed 2026-05-05 | $1.25B derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $1.22B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.20B derived: sum of 2 quarters · filed 2026-02-26 | $1.26B derived: sum of 3 quarters · filed 2026-08-04 | -$32.00M 10-K · filed 2026-02-26 | |||
| 2025-09-28 | -$23.00M 10-Q · filed 2025-11-04 | $42.00M derived: sum of 2 quarters · filed 2026-08-04 | -$1.25B 10-Q · filed 2025-11-04 | -$367.00M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-29 | $65.00M 10-Q · filed 2026-08-04 | -$1.23B 10-Q · filed 2026-08-04 | -$344.00M derived: sum of 3 quarters · filed 2026-08-04 | -$812.00M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-30 | -$1.29B 10-Q · filed 2026-05-05 | -$409.00M derived: sum of 2 quarters · filed 2026-05-05 | -$877.00M derived: sum of 3 quarters · filed 2026-05-05 | -$1.22B derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $886.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $418.00M derived: sum of 2 quarters · filed 2026-02-26 | $74.00M derived: sum of 3 quarters · filed 2026-02-26 | -$114.00M 10-K · filed 2026-02-26 | |||
| 2024-09-29 | -$468.00M 10-Q · filed 2025-11-04 | -$812.00M derived: sum of 2 quarters · filed 2025-11-04 | -$1.00B 10-Q · filed 2025-11-04 | -$408.00M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | -$344.00M 10-Q · filed 2025-08-05 | -$533.00M 10-Q · filed 2025-08-05 | $60.00M derived: sum of 3 quarters · filed 2026-02-26 | -$334.00M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | -$188.00M 10-Q · filed 2025-05-05 | $404.00M derived: sum of 2 quarters · filed 2026-02-26 | $10.00M derived: sum of 3 quarters · filed 2026-02-26 | $131.00M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $592.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $198.00M derived: sum of 2 quarters · filed 2026-02-26 | $319.00M derived: sum of 3 quarters · filed 2026-02-26 | -$165.00M 10-K · filed 2026-02-26 | |||
| 2023-10-01 | -$394.00M 10-Q · filed 2024-11-04 | -$273.00M derived: sum of 2 quarters · filed 2024-11-04 | -$757.00M 10-Q · filed 2024-11-04 | -$722.00M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-07-02 | $121.00M 10-Q · filed 2024-08-05 | -$363.00M 10-Q · filed 2024-08-05 | -$328.00M derived: sum of 3 quarters · filed 2025-02-27 | -$444.00M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-04-02 | -$485.00M 10-Q · filed 2024-05-08 | -$449.00M derived: sum of 2 quarters · filed 2025-02-27 | -$565.00M derived: sum of 3 quarters · filed 2025-02-27 | -$1.18B derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$80.00M derived: sum of 2 quarters · filed 2025-02-27 | -$690.00M derived: sum of 3 quarters · filed 2025-02-27 | -$1.40B 10-K · filed 2025-02-27 | |||
| 2022-10-02 | -$116.00M 10-Q · filed 2023-11-08 | -$726.00M derived: sum of 2 quarters · filed 2023-11-08 | -$1.44B 10-Q · filed 2023-11-08 | -$1.69B derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2022-07-03 | -$610.00M 10-Q · filed 2023-08-09 | -$1.32B 10-Q · filed 2023-08-09 | -$1.57B derived: sum of 3 quarters · filed 2024-02-22 | -$1.25B derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2022-04-03 | -$710.00M 10-Q · filed 2023-05-10 | -$964.00M derived: sum of 2 quarters · filed 2024-02-22 | -$642.00M derived: sum of 3 quarters · filed 2024-02-22 | $181.00M derived: sum of 4 quarters · filed 2024-02-22 | |||
| 2021-12-31 | -$254.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $68.00M derived: sum of 2 quarters · filed 2024-02-22 | $891.00M derived: sum of 3 quarters · filed 2024-02-22 | $1.26B 10-K · filed 2024-02-22 | |||
| 2021-10-03 | $322.00M 10-Q · filed 2022-11-09 | $1.15B derived: sum of 2 quarters · filed 2022-11-09 | $1.52B 10-Q · filed 2022-11-09 | $1.64B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-07-04 | $823.00M 10-Q · filed 2022-08-10 | $1.20B 10-Q · filed 2022-08-10 | $1.32B derived: sum of 3 quarters · filed 2023-02-23 | $1.25B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2021-04-04 | $372.00M 10-Q · filed 2022-05-11 | $496.00M derived: sum of 2 quarters · filed 2023-02-23 | $428.00M derived: sum of 3 quarters · filed 2023-02-23 | $1.16B derived: sum of 4 quarters · filed 2023-02-23 | |||
| 2020-12-31 | $124.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $56.00M derived: sum of 2 quarters · filed 2023-02-23 | $789.00M derived: sum of 3 quarters · filed 2023-02-23 | $515.00M 10-K · filed 2023-02-23 | |||
| 2020-09-27 | -$68.00M 10-Q · filed 2021-11-12 | $665.00M derived: sum of 2 quarters · filed 2021-11-12 | $391.00M 10-Q · filed 2021-11-12 | $680.00M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-06-28 | $733.00M 10-Q · filed 2021-08-12 | $459.00M 10-Q · filed 2021-08-12 | $748.00M derived: sum of 3 quarters · filed 2022-02-24 | $751.00M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-29 | -$274.00M 10-Q · filed 2021-05-13 | $15.00M derived: sum of 2 quarters · filed 2022-02-24 | $18.00M derived: sum of 3 quarters · filed 2022-02-24 | $49.00M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $289.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $292.00M derived: sum of 2 quarters · filed 2022-02-24 | $323.00M derived: sum of 3 quarters · filed 2022-02-24 | $429.00M 10-K · filed 2022-02-24 | |||
| 2019-09-29 | $3.00M 10-Q · filed 2020-11-05 | $34.00M derived: sum of 2 quarters · filed 2020-11-05 | $140.00M 10-Q · filed 2020-11-05 | $262.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $31.00M 10-Q · filed 2020-08-06 | $137.00M 10-Q · filed 2020-08-06 | $259.00M derived: sum of 3 quarters · filed 2021-02-25 | $286.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $106.00M 10-Q · filed 2020-05-07 | $228.00M derived: sum of 2 quarters · filed 2021-02-25 | $255.00M derived: sum of 3 quarters · filed 2021-02-25 | $485.00M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $122.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $149.00M derived: sum of 2 quarters · filed 2021-02-25 | $379.00M derived: sum of 3 quarters · filed 2021-02-25 | $477.00M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $27.00M 10-Q · filed 2019-11-07 | $40.00M 10-Q · filed 2018-11-08 | $257.00M derived: sum of 2 quarters · filed 2019-11-07 | $355.00M 10-Q · filed 2019-11-07 | $370.00M 10-Q · filed 2018-11-08 | ||
| 2018-07-01 | $230.00M 10-Q · filed 2019-08-08 | $213.00M 10-Q · filed 2018-08-09 | $328.00M 10-Q · filed 2019-08-08 | $299.00M 10-Q · filed 2018-08-09 | |||
| 2018-04-01 | $98.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |